ArticleJournal of pharmaceutical sciences2020
Preformulation Characterization and Stability Assessments of Secretory IgA Monoclonal Antibodies as Potential Candidates for Passive Immunization by Oral Administration.
Article in Journal of pharmaceutical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Clinical Assessment of SARS-CoV-2 Antibodies in Oral Fluids Following Infection and Vaccination.Clinical chemistry · 2024Review
- The prospect of orally administered monoclonal secretory IgA (SIgA) antibodies to prevent enteric bacterial infections.Human vaccines & immunotherapeutics · 2022Review
- Plant-derived secretory component gives protease-resistance to Shiga toxin 1-specific dimeric IgA.Plant molecular biology · 2021Article
- Recombinant Human Secretory IgA InducesACS infectious diseases · 2021Article
- IgA as a potential candidate for enteric monoclonal antibody therapeutics with improved gastrointestinal stability.Vaccine · 2020Article
- Human Mucosal IgA Immune Responses against EnterotoxigenicPathogens (Basel, Switzerland) · 2020Review
- A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction.Nature communications · 2020Article
- Inhibition of invasive salmonella by orally administered IgA and IgG monoclonal antibodies.PLoS neglected tropical diseases · 2020Article
- Prophylactic Activity of Orally Administered FliD-Reactive Monoclonal SIgA AgainstFrontiers in immunology · 2020Article
- EnterotoxigenicGut microbesReview
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrheal disease among children in developing countries, and there are no licensed vaccines to protect against ETEC. Passive immunization by oral delivery of ETEC-specific secretory IgAs (sIgAs) could potentially provide an alternative approach for protection in targeted populations. In this study, a series of physiochemical techniques and an in vitro gastric digestion model were used to characterize and compare key structural attributes and stability profiles of 3 anti-heat-labile enterotoxin mAbs (sIgA1, sIgA2, and IgG1 produced in CHO cells). The mAbs were evaluated in terms of primary structure, N-linked glycan profiles, size and aggregate content, relative apparent solubility, conformational stability, and in vitro antigen binding. Compared to IgG1 mAb, sIgA1 and sIgA2 mAbs showed increased sample heterogeneity, especially in terms of N-glycan composition and the presence of higher molecular weight species. The sIgA mAbs showed overall better physical stability and were more resistant to loss of antigen binding activity during incubation at low pH, 37°C with pepsin. These results are discussed in terms of future challenges to design stable, low-cost formulations of sIgA mAbs as an oral supplement for passive immunization to protect against enteric diseases in the developing world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.